Pediatrix Medical Group, Inc. (NYSE:MD) Receives $16.42 Consensus PT from Analysts

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have earned a consensus rating of “Hold” from the six research firms that are covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $16.42.

MD has been the subject of a number of analyst reports. Mizuho boosted their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft lifted their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. StockNews.com cut Pediatrix Medical Group from a “buy” rating to a “hold” rating in a research note on Thursday, December 19th. UBS Group lifted their price objective on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, Macquarie began coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They set an “outperform” rating and a $18.00 target price on the stock.

Pediatrix Medical Group Stock Up 0.8 %

NYSE:MD opened at $13.14 on Tuesday. The firm has a market capitalization of $1.13 billion, a PE ratio of -4.29, a price-to-earnings-growth ratio of 2.00 and a beta of 1.58. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83. The stock has a 50 day moving average of $14.35 and a 200-day moving average of $11.43.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same period last year, the company earned $0.29 earnings per share. The firm’s revenue for the quarter was up .9% on a year-over-year basis. Analysts predict that Pediatrix Medical Group will post 1.26 EPS for the current year.

Insider Buying and Selling

In related news, EVP Mary Ann E. Moore sold 8,108 shares of Pediatrix Medical Group stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the sale, the director now directly owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This represents a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by insiders.

Institutional Trading of Pediatrix Medical Group

A number of hedge funds have recently modified their holdings of the business. State Street Corp raised its position in Pediatrix Medical Group by 1.4% during the third quarter. State Street Corp now owns 3,540,791 shares of the company’s stock valued at $41,038,000 after buying an additional 50,597 shares during the period. Aristeia Capital L.L.C. purchased a new stake in shares of Pediatrix Medical Group during the second quarter worth $687,000. Barclays PLC boosted its position in Pediatrix Medical Group by 302.9% during the third quarter. Barclays PLC now owns 142,087 shares of the company’s stock valued at $1,646,000 after purchasing an additional 106,817 shares during the last quarter. Franklin Resources Inc. acquired a new position in Pediatrix Medical Group in the 3rd quarter worth about $598,000. Finally, Rubric Capital Management LP raised its stake in shares of Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after purchasing an additional 7,241,400 shares in the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.